Concentrated Clotting Factor Composition for Adhesion Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Postoperative adhesions following abdominal surgery are common and can lead to serious medical consequences such as pain, infertility, and bowel obstruction, as they are formed due to excessive activity of cells producing extracellular matrix proteins, and existing solutions fail to effectively prevent or reduce their severity.
Innovation Solution
A purified composition comprising fibrinogen-depleted plasma-derived clotting factors like proaccelerin (factor V), prothrombin (factor II), proconvertin (factor VII), and Stuart-Prower factor (factor X), concentrated to enhance clotting at surgical sites and applied topically to reduce adhesion formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional adhesion prevention methods are used, then adhesion formation is reduced, but the effectiveness is insufficient to prevent serious medical consequences
Solution Approach 1:
The patent concentrates specific clotting factors (V, VII, X, and prothrombin) to high levels (300%-2000% above normal plasma concentrations) to enhance the coagulation response at the surgical site, creating a more reliable adhesion prevention effect through parameter optimization rather than using standard concentrations
Solution Approach 2:
The patent extracts and isolates specific clotting factors (V, VII, X, and prothrombin) from plasma while deliberately removing or depleting fibrinogen, creating a targeted composition that provides adhesion prevention without the harmful effects of excessive fibrin deposition associated with conventional plasma-based solutions
2Strength
If fibrinogen-rich plasma is applied to promote clotting, then clot formation is enhanced, but excessive fibrin deposition occurs leading to increased adhesion formation
Solution Approach 1:
The patent converts the potential harm of fibrinogen (which can lead to excessive fibrin deposition and adhesion formation) into a benefit by completely depleting fibrinogen from the composition, while retaining and concentrating other clotting factors that promote clotting through alternative pathways, thus achieving clot formation without the harmful fibrin byproduct
Solution Approach 2:
The patent creates a localized clotting environment by applying a composition with highly concentrated specific clotting factors directly at the surgical site, where these factors activate the coagulation cascade locally to form clots that prevent adhesion without causing systemic or widespread fibrin deposition
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces adhesion severity by forming a local clot at the wound site, preventing excessive fibrin deposition and adhesion formation, thereby improving healing and reducing long-term complications.
Implementation Method 1
The composition effectively reduces adhesion severity by forming a local clot at the wound site
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The present invention provides a composition, comprising: proaccelerin (factor V) and at least one factor selected from the group consisting of: prothrombin (factor II), proconvertin (factor VII), and Stuart-Prower factor (factor X), wherein an amount of the proaccelerin in the composition is between 75% to 750% compared to an amount of proaccelerin in a blood plasma, and wherein an amount of the at least one factor is from 150% to 3000% compared to an amount of the at least one factor in the blood plasma; wherein the amount of proaccelerin and the at least one factor in the composition is determined by extrapolating an observed activity of the composition at a concentration of 500mM NaCl, using a prothrombin complementation assay using a standard curve constructed using the blood plasma.